TOP TEN perturbations for 1553424_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553424_at
Selected probe(set): 1553424_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553424_at (1553424_at) across 6673 perturbations tested by GENEVESTIGATOR:

lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)

Relative Expression (log2-ratio):-1.1176252
Number of Samples:4 / 2
Experimental lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)

Relative Expression (log2-ratio):0.88913536
Number of Samples:2 / 4
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)

Relative Expression (log2-ratio):-0.8748112
Number of Samples:43 / 2
Experimental lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):0.8065605
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

strabismus study 1 / normal extraocular medial rectus muscle tissue

Relative Expression (log2-ratio):-0.7966132
Number of Samples:3 / 4
Experimental strabismus study 1
Human extraocular medial rectus muscle tissue sample obtained from patients with strabismus after strabismus correction surgery.
Control normal extraocular medial rectus muscle tissue
Postmortem human extraocular medial rectus tissue samples from healthy donors without any ophthalmologic disease.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.77604246
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

HCC study 27 (elder; validation) / HCC study 27 (elder; training)

Relative Expression (log2-ratio):0.773386
Number of Samples:10 / 32
Experimental HCC study 27 (elder; validation)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a validation cohort.
Control HCC study 27 (elder; training)
Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a training cohort.

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):0.75852966
Number of Samples:2 / 22
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted).

pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)

Relative Expression (log2-ratio):0.7393122
Number of Samples:8 / 30
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (infant)
Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive.

pediatric septic shock study 3 (toddler; subclass A) / pediatric septic shock study 3 (toddler)

Relative Expression (log2-ratio):0.73878574
Number of Samples:4 / 23
Experimental pediatric septic shock study 3 (toddler; subclass A)
Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (toddler)
Whole blood obtained from toddlers (2 – 5 years) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Two children did not survive.